Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ClearPoint Neuro (CLPT)
NASDAQ:CLPT
Holding CLPT?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.16Last Year’s EPS
-$0.18Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 15.83%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in revenue and strategic progress across all business segments, alongside a strong cash position and no debt. However, there was a noted decrease in service revenue and continued operational cash burn, albeit reduced.Company Guidance
During the Q3 2024 earnings call for ClearPoint Neuro, the company reported a record revenue of $8.1 million, marking a 41% increase compared to the same quarter in 2023. This growth was driven by strong performance across four key growth pillars: Biologics and Drug Delivery, Neurosurgery Navigation, Therapy and Access Products, and global expansion. Each segment experienced over 20% growth, contributing to a reduction in operational cash burn and an improvement in gross margin to 60% from 57% in Q3 2023. The company also highlighted a 353% increase in Biologics and Drug Delivery product revenue, despite a $0.7 million decrease in service revenue. Furthermore, ClearPoint Neuro's cash position stood at $21.6 million with no outstanding debt, following an early repayment of a $10.1 million convertible loan. Operational cash burn was reduced to $1.2 million, a 33% decrease from the previous year, with a trailing 12-month reduction of 43%.Record Revenue Quarter
ClearPoint Neuro reported a record revenue of $8.1 million in Q3 2024, marking a 41% growth compared to the same quarter in 2023.
Growth Across All Segments
All four growth pillars - Biologics and Drug Delivery, Neurosurgery Navigation, Therapy and Access Products, and Global Scale - grew more than 20% in the third quarter.
Significant Increase in Biologics and Drug Delivery
Biologics and Drug Delivery saw a 353% increase in product revenue, indicating progress in pharmaceutical partnerships.
Strong Cash Position
As of September 30, 2024, ClearPoint Neuro had $21.6 million in cash and cash equivalents and no outstanding debt.
Accelerated Customer Site Activations
19 new customer sites were activated in 2024, surpassing the typical 6-8 per year.
---
CLPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $13.42 | $11.65 | -13.19% |
| Aug 07, 2024 | $6.44 | $9.06 | +40.68% |
| May 07, 2024 | $5.89 | $5.99 | +1.70% |
| Mar 12, 2024 | $6.05 | $7.17 | +18.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ClearPoint Neuro (CLPT) report earnings?
ClearPoint Neuro (CLPT) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is ClearPoint Neuro (CLPT) earnings time?
ClearPoint Neuro (CLPT) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLPT EPS forecast?
CLPT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.16.
---